Calder Biosciences, Inc., a next-generation vaccine company, has published an article that debuts and validates the application of Calder’s ‘3D Vaxlock’ platform technology. When applied to the Respiratory Syncytial Virus (RSV) F protein as a vaccine immunogen, Calder’s 3D Vaxlock technology achieves an unprecedented 11X more potent immune response than the standard industry comparator.
New study explores next-generation vaccine technology for RSV
